Not provided
Not provided
Not provided
Not provided
Not provided
Evidence that the dose is insufficient.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Verapamil has also been shown to improve eosinophilic inflammation in an animal model of asthma and also functions as a P-glycoprotein(P-gp) inhibitor. A major subtype of chronic rhinosinusitis(CRS) is characterized by eosinophilic inflammation as well as P-gp overexpression. The goal of this study is to therefore see whether Verapamil may be used to treat CRS.
Chronic rhinosinusitis (CRS) impacts more than 30 million Americans resulting in $6.9 to $9.9 billion in annual healthcare expenditures and $12.8 billion in productivity costs. The prevalence of Chronic Rhinosinusitis with Nasal Polyps(CRSwNP) in Europe has been estimated to be 2-4.3% and is thought to be similar in the United States. Corticosteroids remain the mainstay of treatment although novel therapies are being developed based on an evolving understanding of the inflammatory pathways involved in disease pathogenesis. CRSwNP is characterized by the presence of edematous polypoid mucosa and predominantly eosinophilic inflammation. Recent evidence has focused on the sinonasal epithelial cell as a primary driver of the local dysregulated immune response through secretion of type 2 helper T-cell(Th2) promoting cytokines. While these studies suggest that epithelial cells are capable of orchestrating a local immune response, the mechanisms responsible for regulating cytokine secretion are poorly understood and may be influenced by the efflux function of epithelial P-glycoprotein(P-gp).
P-gp is a 170 kiloDalton membrane protein which belongs to sub-family B of the adenosine triphosphate(ATP)-binding cassette(ABC) transporter superfamily. P-gp utilizes ATP hydrolysis to transport a wide range of substrates across the plasma membrane. P-gp mediated transport has been observed in the regulation of cytokine secretion in both human T-cells as well as sinonasal epithelial cells implicating a potential immunomodulatory role. Studies by our group have demonstrated that P-gp is overexpressed in the mucosa of patients with Th2 skewed CRS endotypes including CRSwNP and is capable of regulating the secretion of Th2 polarizing cytokines. Together, these findings suggest that P-gp participates in the non-canonical regulation of cytokine secretion within CRSwNP and may thereby represent a druggable target.
Verapamil Hydrochloride(HCl) was one of the first inhibitors of P-gp to be identified in 1982 and also functions as a calcium channel blocker(CCB). Verapamil has since been categorized as a first generation P-gp inhibitor as more potent and selective 2nd and 3rd generation molecules were subsequently developed for use as chemotherapy sensitizers. Several studies, including those by our group, have reported that Verapamil is capable of modulating inflammatory responses in human T-cells, animal models of asthma, and nasal polyps. Using an organotypic explant model, we have previously shown that Verapamil has similar effects to dexamethasone in its ability to abrogate Interleukin(IL)-5, IL-6, and Thymic Stromal Lymphopoietin secretion. While Verapamil is cardioactive, it is considered the first-line prophylactic drug for cluster headache and is usually well tolerated by otherwise healthy patients.
In light of our prior studies demonstrating the immunomodulatory role of P-gp in promoting Th2 skewing cytokine secretion in CRSwNP, we hypothesized that low dose Verapamil HCl monotherapy would be safe and effective in the treatment of CRSwNP.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment | Experimental | Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks |
|
| Control | Placebo Comparator | Placebo, capsules for oral administration, TID, for 8 weeks |
|
| Open Label | Experimental | Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Verapamil HCl | Drug | Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps. |
| Measure | Description | Time Frame |
|---|---|---|
| Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22) | Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome | baseline to week 8 |
| Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS) | Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. | baseline to week 8 |
| Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22) | Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome | baseline to week 56 |
| Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS) | Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. | baseline to week 56 |
| Measure | Description | Time Frame |
|---|---|---|
| Objective Sinonasal Symptoms on Lund-Kennedy Score(LKS) | Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. | baseline to week 8 |
| Objective Sinonasal Symptoms on Lund-McKay Score(LMS) |
| Measure | Description | Time Frame |
|---|---|---|
| Heart Rate | Mean change between baseline and week 8 measurements. | |
| Systolic Blood Pressure | Mean change between baseline and week 8 measurements | |
| Diastolic Blood Pressure |
Inclusion Criteria:
Exclusion Criteria:
Patients with the following comorbidities:
Patients taking the following medications:
Patients with cardiac or conduction abnormality picked up by screening EKG
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Benjamin S Bleier, MD | Massachusetts Eye and Ear Infirmary | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts Eye and Ear Infirmary | Boston | Massachusetts | 02114 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23172039 | Background | Chin D, Harvey RJ. Nasal polyposis: an inflammatory condition requiring effective anti-inflammatory treatment. Curr Opin Otolaryngol Head Neck Surg. 2013 Feb;21(1):23-30. doi: 10.1097/MOO.0b013e32835bc3f9. | |
| 22887970 | Background | Poetker DM, Jakubowski LA, Lal D, Hwang PH, Wright ED, Smith TL. Oral corticosteroids in the management of adult chronic rhinosinusitis with and without nasal polyps: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2013 Feb;3(2):104-20. doi: 10.1002/alr.21072. Epub 2012 Aug 7. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Treatment | Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks Verapamil HCl: Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps. |
| FG001 | Control | Placebo, capsules for oral administration, TID, for 8 weeks Placebo: Capsule with the same characteristics (size, color, smell) as Verapamil HCl. |
| FG002 | Open Label | Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Double-Blind Period |
|
| ||||||||||||||||||
| Open Label Period |
|
Intention-to-treat analysis
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Treatment | Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks Verapamil HCl: Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22) | Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome | Intention-to-treat analysis | Posted | Least Squares Mean | Standard Error | units on a scale | baseline to week 8 |
|
1 year
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Treatment | Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks Verapamil HCl: Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acute Sinusitis | General disorders | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Benjamin Bleier | Massachusetts Eye and Ear Infirmary | (617) 573-6966 | Benjamin_Bleier@MEEI.HARVARD.EDU |
Not provided
| ID | Term |
|---|---|
| D012852 | Sinusitis |
| D009298 | Nasal Polyps |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D010254 | Paranasal Sinus Diseases |
| D009668 | Nose Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014700 | Verapamil |
| ID | Term |
|---|---|
| D010627 | Phenethylamines |
| D005021 | Ethylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Placebo | Other | Capsule with the same characteristics (size, color, smell) as Verapamil HCl. |
|
Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome.
| Week 8 |
| Mean change between baseline and week 8 measurements |
| 22133887 | Background | Khakzad MR, Mirsadraee M, Mohammadpour A, Ghafarzadegan K, Hadi R, Saghari M, Meshkat M. Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. Pulm Pharmacol Ther. 2012 Apr;25(2):163-8. doi: 10.1016/j.pupt.2011.11.001. Epub 2011 Nov 25. |
| 20118567 | Background | Matsumori A, Nishio R, Nose Y. Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells. Circ J. 2010 Mar;74(3):567-71. doi: 10.1253/circj.cj-09-0467. Epub 2010 Jan 30. |
| 22659089 | Background | Hashioka S, Klegeris A, McGeer PL. Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. Neuropharmacology. 2012 Sep;63(4):685-91. doi: 10.1016/j.neuropharm.2012.05.033. Epub 2012 May 30. |
| 16673153 | Background | Li G, Qi XP, Wu XY, Liu FK, Xu Z, Chen C, Yang XD, Sun Z, Li JS. Verapamil modulates LPS-induced cytokine production via inhibition of NF-kappa B activation in the liver. Inflamm Res. 2006 Mar;55(3):108-13. doi: 10.1007/s00011-005-0060-y. |
| 2686646 | Background | Bacon KB, Westwick J, Camp RD. Potent and specific inhibition of IL-8-, IL-1 alpha- and IL-1 beta-induced in vitro human lymphocyte migration by calcium channel antagonists. Biochem Biophys Res Commun. 1989 Nov 30;165(1):349-54. doi: 10.1016/0006-291x(89)91076-0. |
| 23773141 | Background | Becker WJ. Cluster headache: conventional pharmacological management. Headache. 2013 Jul-Aug;53(7):1191-6. doi: 10.1111/head.12145. Epub 2013 Jun 14. |
| 17698788 | Background | Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology. 2007 Aug 14;69(7):668-75. doi: 10.1212/01.wnl.0000267319.18123.d3. |
| 21258839 | Background | Lanteri-Minet M, Silhol F, Piano V, Donnet A. Cardiac safety in cluster headache patients using the very high dose of verapamil (>/=720 mg/day). J Headache Pain. 2011 Apr;12(2):173-6. doi: 10.1007/s10194-010-0289-x. Epub 2011 Jan 22. |
| 22764607 | Background | Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald PJ. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012 Mar;23:3 p preceding table of contents, 1-298. |
| 19793277 | Background | Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009 Oct;34(5):447-54. doi: 10.1111/j.1749-4486.2009.01995.x. |
| NOT COMPLETED |
|
|
| BG001 | Control | Placebo, capsules for oral administration, TID, for 8 weeks Placebo: Capsule with the same characteristics (size, color, smell) as Verapamil HCl. |
| BG002 | Open Label | Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year Verapamil HCl: Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps. |
| BG003 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 | Control | Placebo, capsules for oral administration, TID, for 8 weeks Placebo: Capsule with the same characteristics (size, color, smell) as Verapamil HCl. |
|
|
|
| Primary | Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS) | Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. | Intention-to-treat analysis | Posted | Least Squares Mean | Standard Error | units on a scale | baseline to week 8 |
|
|
|
|
| Secondary | Objective Sinonasal Symptoms on Lund-Kennedy Score(LKS) | Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. | Intention-to-treat analysis | Posted | Least Squares Mean | Standard Error | units on a scale | baseline to week 8 |
|
|
|
|
| Secondary | Objective Sinonasal Symptoms on Lund-McKay Score(LMS) | Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. | Intention-to-treat analysis | Posted | Mean | Standard Deviation | units on a scale | Week 8 |
|
|
|
|
| Other Pre-specified | Heart Rate | Posted | Mean | Standard Deviation | beats per minute | Mean change between baseline and week 8 measurements. |
|
|
|
|
| Other Pre-specified | Systolic Blood Pressure | Posted | Mean | Standard Deviation | mmHg | Mean change between baseline and week 8 measurements |
|
|
|
|
| Other Pre-specified | Diastolic Blood Pressure | Posted | Mean | Standard Deviation | mmHg | Mean change between baseline and week 8 measurements |
|
|
|
|
| Primary | Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22) | Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome | Intention-to-treat analysis | Posted | Mean | Standard Error | units on a scale | baseline to week 56 |
|
|
|
| Primary | Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS) | Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. | Intention-to-treat analysis | Posted | Mean | Standard Error | units on a scale | baseline to week 56 |
|
|
|
| 0 |
| 10 |
| 8 |
| 10 |
| EG001 | Control | Placebo, capsules for oral administration, TID, for 8 weeks Placebo: Capsule with the same characteristics (size, color, smell) as Verapamil HCl. | 0 | 10 | 5 | 10 |
| EG002 | Open Label | Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year Verapamil HCl: Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps. | 0 | 29 | 18 | 29 |
| Dizziness | Ear and labyrinth disorders | Non-systematic Assessment |
|
| Swelling of Hands or Feet | General disorders | Non-systematic Assessment |
|
| Slow, Fast or Irregular Heart Rate | Cardiac disorders | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Non-systematic Assessment |
|
| Heartburn | Gastrointestinal disorders | Non-systematic Assessment |
|
| Lightheadedness | General disorders | Non-systematic Assessment |
|
| Headache | General disorders | Non-systematic Assessment |
|
| Fainting | General disorders | Non-systematic Assessment |
|
| Blurred Vision | General disorders | Non-systematic Assessment |
|
| Nausea | General disorders | Non-systematic Assessment |
|
| Tiredness | General disorders | Non-systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
|
| Abdominal Pain | Gastrointestinal disorders | Non-systematic Assessment |
|
| Yellow Eyes or Skin | Hepatobiliary disorders | Non-systematic Assessment |
|
Not provided
Not provided
| D012140 |
| Respiratory Tract Diseases |
| D010038 | Otorhinolaryngologic Diseases |
| D011127 | Polyps |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| Title | Measurements |
|---|---|
|
| Surgical Completers, baseline |
|
|
| Surgical Completers, week 12 |
|
|
| Title | Measurements |
|---|---|
|
| Surgical Completers, baseline |
|
|
| Surgical Completers, week 12 |
|
|